Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review.

European journal of medicinal chemistry - 5 Dec 2022

Wang Kuanglei, Zhang Huicong, Tian Yongshou

Abstract excerpt

Influenza with a tendency to cause pandemic and epidemic is an infectious disease with a high of morbidity and mortality. Neuraminidase (NA) inhibitors are proved to prevent and treat influenza. Among the four Neuraminidase inhibitors (NAIs) licensed, oseltamivir is most commonly used. With the extensive usage, several variants containing mutant NAs especially H274Y point mutation exhibit reduced susceptibility....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycoside Hydrolases

Share to Guanidines

Share to Influenza, Human

Share to Neuraminidase

Share to Oseltamivir

Share to Zanamivir

Source

Identifiers

PMID: 36055001
DOI: 10.1016/j.ejmech.2022.114711

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review.PMID 36055001Read ↗

Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.Semantic proximity Read ↗

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceSemantic proximity Read ↗

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.Semantic proximity Read ↗

Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor DesignSemantic proximity Read ↗

Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.Semantic proximity Read ↗

Influenza pharmacotherapy: present situation, strategies and hopes.Semantic proximity Read ↗

[Analysis of the Neuraminidase Amino Acid Sequences of Influenza A/H1N1pdm09, A/H3N2, and B Viruses Isolated from Influenza Patients in the 2013/14 Japanese Influenza Season].Semantic proximity Read ↗

Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.Semantic proximity Read ↗

H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site.Semantic proximity Read ↗

Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.Semantic proximity Read ↗

Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.Semantic proximity Read ↗

Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.